MAPT and Parkinson disease: Here we report: (1) Synthesis of INFT 11 and the chlorinated (ClNFT 12) and fluorinated (FNFT 13) analogs (Figure 3); (2) Molecular docking studies to human Tau; (3) Radiosynthesis of [125I]INFT; (4) Measurement of binding affinity of the analogs for Tau using postmortem AD brain; (5) Autoradiographic studies in postmortem AD, Parkinson’s disease (PD) and cognitively normal (CN) brain sections, and (6) Drug effects (MAO-A and MAO-B) on the binding of [125I]INFT in postmortem AD brains.